X-Linked Intellectual Disability: Clinical Trials

370 trials for X-Linked Intellectual Disability, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

183 completed, 53 recruiting, 34 unknown, 33 terminated. 128 Phase 2, 62 Phase 3, 58 Phase 1, 52 Not applicable, 9 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2128Completed 74, Active not recruiting 13, Terminated 11, Recruiting 10, Unknown 6, Withdrawn 6, Not yet recruiting 4, Enrolling by invitation 2, Suspended 2
Phase 362Completed 30, Active not recruiting 13, Terminated 11, Enrolling by invitation 2, Not yet recruiting 2, Recruiting 2, Unknown 1, Withdrawn 1
Phase 158Completed 35, Active not recruiting 5, Recruiting 5, Terminated 5, Withdrawn 4, Unknown 3, Enrolling by invitation 1
Not applicable52Completed 26, Recruiting 10, Unknown 10, Active not recruiting 2, Not yet recruiting 2, Enrolling by invitation 1, Terminated 1
Phase 49Completed 6, Active not recruiting 1, Recruiting 1, Withdrawn 1
Early Phase 14Completed 2, Active not recruiting 1, Terminated 1

Follow X-Linked Intellectual Disability: new trials by email Literature Review of X-Linked Intellectual Disability trials Research Report on X-Linked Intellectual Disability

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Phase 2 / Phase 3Not yet recruitingFenix Innovation Group402027-07-012026-09-09
IT and IV Lentiviral Gene Therapy for X-ALD
Intrathecal and intravenous LV gene therapy - X-linked Adrenoleukodystrophy
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-09-01
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS
Codabakalner, Placebo - Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD)
Phase 2 / Phase 3Not yet recruitingSpinogenix1202026-12-012026-10-09
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
Bionetide, Placebo - Rett Syndrome
Phase 3RecruitingBiomed Industries, Inc.2102026-09-302026-03-27
A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome
Rett-T, Placebo - Rett Syndrome
Phase 2RecruitingHolland Bloorview Kids Rehabilitation Hospital352026-08-242026-09-02
NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease
Droxidopa Oral Product, Placebo Control - Menkes Disease
Phase 1 / Phase 2RecruitingStephen G. Kaler62026-08-102026-10-05
Adapting a Psychosocial Support Intervention for the Rett Syndrome Community
Those who have patients prescribed Daybue, Caregiver Speaks + Daybue - Rett Syndrome, Family Caregivers
Not applicableNot yet recruitingColorado State University602026-08-012026-07-28
The Neurocognitive Bases of Trust in Intellectual Disability
Confidence adjustment assessment, clinical assessment, Cognitive assessment - Down Syndrome (Trisomy 21), Fragile X Syndrome (FXS)
RecruitingHospices Civils de Lyon1122026-07-172026-08-05
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
fenfluramine hydrochloride, Placebo - Rett Syndrome
Phase 3RecruitingUCB BIOSCIENCES, Inc.2002026-07-142026-10-15
Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome
CTH120, CTH120 placebo hard capsules - Fragile X Syndrome (FXS), Fragile X Syndrome
Phase 2RecruitingConnecta Therapeutics, S.L.302026-05-212026-07-17
Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
TSHA-102 - Rett Syndrome
Phase 3Active not recruitingTaysha Gene Therapies, Inc.42026-05-082026-08-19
Optical Imaging in X-linked Disorders.
Clinical assessment, Parental questionnaires, Cognitive assessment - Fragile X Syndrome (FXS), Creatine Transporter Deficiency
Not applicableRecruitingHospices Civils de Lyon1182026-03-302026-05-15
Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome
Vorinostat (SAHA), Placebo - Rett Syndrome
Phase 1RecruitingUnravel Biosciences, Inc.152026-03-152026-09-17
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD)
RecruitingHealing Hope International1002026-03-012026-03-25
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
SRX246, Placebo - Aggressive Behavior in Fragile X Syndome
Phase 2Not yet recruitingAzevan Pharmaceuticals802026-03-012026-01-09
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
RGX-121-3102 - MPS II, Hunter Syndrome (MPS II)
Phase 3Active not recruitingREGENXBIO Inc.22025-11-252026-06-04
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379 - Fragile X Syndrome
Phase 2RecruitingMirum Pharmaceuticals, Inc.602025-11-222026-09-29
Lamivudine as a Novel Clinical Effort for Rett Syndrome
Lamivudine - Rett Syndrome
Phase 2Enrolling by invitationMaria Denise Fernandes Carvalho de Andrade102025-11-052026-06-10
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)
Glycerol Phenylbutyrate 1100 MG/ML [Ravicti] - Pyruvate Dehydrogenase Complex Deficiency Disease
Phase 2RecruitingAssistance Publique - Hôpitaux de Paris152025-10-012026-03-31
Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals With Fragile-X Syndrome
CBD Oral Solution, Placebo - Fragile X Syndrome
Phase 2RecruitingUniversité de Sherbrooke402025-09-012026-08-28

Showing 20 of 370. Sign in to see all of them.

Narrower conditions

Fragile X Syndrome (113)  ·  Rett Syndrome (95)  ·  Mucopolysaccharidosis II (77)  ·  Adrenoleukodystrophy (62)  ·  Sudden Infant Death (34)  ·  Mucopolysaccharidosis I (24)  ·  Intellectual Disability (21)  ·  Leukodystrophy, Metachromatic (21)  ·  Autism Spectrum Disorder (19)  ·  Autistic Disorder (18)  ·  Mucopolysaccharidoses (18)  ·  Genetic Diseases, Inborn (17)  ·  Genetic Diseases, X-Linked (17)  ·  Leukodystrophy, Globoid Cell (17)  ·  Lysosomal Storage Diseases (17)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (368)  ·  Heredodegenerative Disorders, Nervous System (360)  ·  Nervous System Diseases (359)  ·  Neurologic Manifestations (358)  ·  Neurobehavioral Manifestations (357)  ·  Genetic Diseases, Inborn (353)  ·  Genetic Diseases, X-Linked (353)  ·  Intellectual Disability (348)  ·  Nutritional and Metabolic Diseases (172)  ·  Metabolic Diseases (158)  ·  Metabolism, Inborn Errors (149)  ·  Congenital Abnormalities (126)  ·  Chromosome Disorders (114)  ·  Sex Chromosome Disorders (112)

Interventions

idursulfase (14)  ·  trofinetide (8)  ·  mavoglurant (6)  ·  Alemtuzumab (5)  ·  Metformin (5)  ·  arbaclofen placarbil (5)  ·  BPN14770 (4)  ·  Dextromethorphan (4)  ·  Donepezil (4)  ·  Injections (4)  ·  Lovastatin (4)  ·  Melphalan (4)  ·  Minocycline (4)  ·  Stem Cell Transplantation (4)  ·  gaboxadol (4)

Sponsors

Shire (15)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (9)  ·  Seaside Therapeutics, Inc. (9)  ·  Children's Hospital Medical Center, Cincinnati (8)  ·  Stanford University (8)  ·  JCR Pharmaceuticals Co., Ltd. (7)  ·  Masonic Cancer Center, University of Minnesota (7)  ·  Novartis Pharmaceuticals (6)  ·  REGENXBIO Inc. (6)  ·  University of California, Davis (6)  ·  Assistance Publique - Hôpitaux de Paris (5)  ·  Genetix Biotherapeutics Inc. (5)  ·  Green Cross Corporation (5)  ·  Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (5)  ·  Rett Syndrome Research Trust (5)

Countries

United States (235)  ·  United Kingdom (45)  ·  France (40)  ·  Spain (37)  ·  Italy (36)  ·  Canada (32)  ·  Germany (27)  ·  Australia (25)  ·  Netherlands (18)  ·  Brazil (15)  ·  Argentina (11)  ·  China (10)  ·  Belgium (8)  ·  Israel (8)  ·  Mexico (8)

Top investigators

Elizabeth Berry-Kravis, MD, PhD (5)  ·  Paul Orchard, MD (5)  ·  Alan Percy, MD (4)  ·  Joanne Kurtzberg, MD (4)  ·  Randi J Hagerman, MD (4)  ·  Allan L Reiss (3)  ·  Bryan King, MD, PhD (3)  ·  Craig Erickson, MD (3)  ·  Craig Erikson, MD (3)  ·  Elizabeth Berry-Kravis, MD (3)  ·  James McCracken, MD (3)  ·  Jeremy Veenstra-VanderWeele, MD (3)

Results publications

PMID 37460385, PMID 33395098, PMID 38363467, PMID 39383458, PMID 19772971, PMID 21586746, PMID 23035069, PMID 24399845, PMID 25071871, PMID 25283752, PMID 25801175, PMID 26764156, PMID 26855682, PMID 35568815, PMID 35794169, PMID 35961250, PMID 37915038, PMID 38723617, PMID 39383459, PMID 10331611, PMID 10517635, PMID 10595921, PMID 10797443, PMID 11231629, PMID 11241498, PMID 11399225, PMID 12103288, PMID 15368082, PMID 15492353, PMID 15521982, PMID 15551335, PMID 15923132, PMID 16278898, PMID 16411192, PMID 17482283, PMID 18203205, PMID 18256395, PMID 18337588, PMID 18752978, PMID 19194885, PMID 19833552, PMID 19892975, PMID 19914908, PMID 20032810, PMID 20231667, PMID 20497190, PMID 20652413, PMID 20937127, PMID 21059347, PMID 21104896

NIH funding

2023 (4), 2019 (3), 2009 (2), 2014 (2), 2018 (2), 2025 (2), K23HD109375 (2), U54HD061222 (2), U54NS065768 (2), 2004 (1), 2015 (1), K23MH077554 (1), K23NS087151 (1), P01HD024448 (1), R01AG076678 (1)